Vanguard Group’s ARS Pharmaceuticals SPRY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $56.9M | Sell |
3,262,673
-225,620
| -6% | -$3.94M | ﹤0.01% | 2067 |
|
|
2025
Q1 | $43.9M | Buy |
3,488,293
+23,341
| +0.7% | +$294K | ﹤0.01% | 2145 |
|
|
2024
Q4 | $36.6M | Buy |
3,464,952
+115,656
| +3% | +$1.22M | ﹤0.01% | 2294 |
|
|
2024
Q3 | $48.6M | Buy |
3,349,296
+98,369
| +3% | +$1.43M | ﹤0.01% | 2190 |
|
|
2024
Q2 | $27.7M | Buy |
3,250,927
+364,472
| +13% | +$3.1M | ﹤0.01% | 2403 |
|
|
2024
Q1 | $29.5M | Buy |
2,886,455
+779,969
| +37% | +$7.97M | ﹤0.01% | 2407 |
|
|
2023
Q4 | $11.5M | Sell |
2,106,486
-14,803
| -0.7% | -$81.1K | ﹤0.01% | 2865 |
|
|
2023
Q3 | $8.02M | Buy |
2,121,289
+276,097
| +15% | +$1.04M | ﹤0.01% | 3009 |
|
|
2023
Q2 | $12.4M | Buy |
1,845,192
+147,555
| +9% | +$989K | ﹤0.01% | 2824 |
|
|
2023
Q1 | $11.1M | Buy |
1,697,637
+9,717
| +0.6% | +$63.3K | ﹤0.01% | 2883 |
|
|
2022
Q4 | $14.4M | Buy |
1,687,920
+600,749
| +55% | +$5.12M | ﹤0.01% | 2792 |
|
|
2022
Q3 | $5.74M | Buy |
1,087,171
+30,507
| +3% | +$161K | ﹤0.01% | 3248 |
|
|
2022
Q2 | $4.48M | Buy |
1,056,664
+233,368
| +28% | +$989K | ﹤0.01% | 3428 |
|
|
2022
Q1 | $2.89M | Sell |
823,296
-488,370
| -37% | -$1.71M | ﹤0.01% | 3793 |
|
|
2021
Q4 | $8.74M | Sell |
1,311,666
-357,428
| -21% | -$2.38M | ﹤0.01% | 3293 |
|
|
2021
Q3 | $16.7M | Buy |
1,669,094
+673,544
| +68% | +$6.72M | ﹤0.01% | 2960 |
|
|
2021
Q2 | $30.8M | Sell |
995,550
-89,942
| -8% | -$2.78M | ﹤0.01% | 2618 |
|
|
2021
Q1 | $47.4M | Buy |
1,085,492
+1,035,492
| +2,071% | +$45.2M | ﹤0.01% | 2345 |
|
|
2020
Q4 | $2.32M | Buy |
+50,000
| New | +$2.32M | ﹤0.01% | 3626 |
|